Molecular aspects of myeloproliferative neoplasms
- 27 February 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 91 (2), 165-173
- https://doi.org/10.1007/s12185-010-0530-z
Abstract
During these past 5 years several studies have provided major genetic insights into the pathogenesis of the so-called classical myeloproliferative neoplasms (MPNs): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The discovery of the JAK2V617F mutation first, then of the JAK2 exon 12 and MPLW515 mutations, have modified the understanding of these diseases, their diagnosis, and management. Now it is established that almost 100% of PV patients present a JAK2 mutation. Nearly 60% of ET patients and 50% of patients with PMF have the JAK2V617F mutation. The MPLW515 mutations are also present in a small proportion of ET and PMF patients. These mutations are oncogenic events that cause these disorders; however, they do not explain the heterogeneity of the entities in which they occur. Genetic defects have not been yet identified in around 40% of ET and PMF. There are likely additional somatic genetic factors important for the MPN phenotype like the recently described TET2, ASXL1, and CBL mutations. Moreover, polymorphisms in the JAK2 gene have been recently described as associated with MPN. Additional studies of large cohorts are required to dissect the genetic events in MPNs and the mechanisms of these oncogenic cooperations.Keywords
This publication has 66 references indexed in Scilit:
- ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1Journal of Biological Chemistry, 2010
- Mutation inTET2in Myeloid CancersNew England Journal of Medicine, 2009
- Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1Science, 2009
- A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasmsNature Genetics, 2009
- Transgenic expression of JAK2V617F causes myeloproliferative disorders in miceBlood, 2008
- Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosisBlood, 2007
- The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraBlood, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisNew England Journal of Medicine, 2007
- Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosisBlood, 2006
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005